anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain a virus-inactivated globulin, having excellent stability and water-solubility, by heating a virus-contaminated immunoglobulin in dried state preferably in the presence of a specific stabilizing agent until the virus is inactivated. CONSTITUTION:An immunoglobulin possibly contaminated with virus, e.g. human-, equine- or mouse-originated monoclonal or polyclonal antibody, preferably IgG, IgA or IgM, is heat-treated in dried state, preferably under total humidity of &lt;=3% in the presence of a stabilizing agent (e.g. glycine) until the virus is inactivated. The concentration of the stabilizer is preferably 0.01-2w/v% for the 0.01-2w/v% solution of monoclonal immunoglobulin or 2-8-w/v% solution of polyclonal immunoglobulin. An immunoglobulin having excellent stability and water-solubility can be prepared at the some time to the inactivation of the contaminant virus.
A system ingests the purchases of a user at various retail outlets and are analyzed to characterize a user&#39;s taste profile as well as the complexity and effort of meals prepared by the user. A meal plan including the preparation of recipes corresponding to the user&#39;s taste, complexity, and effort profiles. Meal plan media including instructions for preparing the meals of the meal plan are provided. Interactions or lack thereof and the date of interactions are monitored and analyzed to determine whether a meal was executed and the date of execution. A weekly schedule profile of the user is developed based on the complexity and effort scores of meals and the determination of whether the meals are or are not executed. Subsequent meal plans are generated based on the schedule profile and the taste profile updated per determinations of which meals are executed.
This invention provides a polysaccharide containing chitosan, manufacturing method thereof, and pharmaceuticals and food containing such polysaccharide. The polysaccharide containing chitosan was obtained by heating mushroom in a concentrated caustic alkali aqueous solution, then separating the solid content from solution and dissolved it in an organic acid aqueous solution, and thereto the alcohol or the caustic alkali was added to produce the precipitation, then the precipitate was subjected to wash and dry. Such polysaccharide containing chitosan is a compound, in which the glucosamine homopolymer and glucan is bonded by covalent bond, whereas the constructed molar ratio of glucosamine and glucan is 1 to 5:5 to 1, with a molecular weight of 150000 approximately. Said polysaccharide containing beta(1 -&gt; 4)linkage and beta(1 -&gt; 6)linkage but no beta(1 -&gt; 3)linkage. Such polysaccharide does not contain protein and reducing polysaccharide. Such polysaccharide containing chitosan is useful in prophylaxis and treatment of living habit diseases such as hypertension, diabetes and the like.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition for regulating marker protein levels widely usable in food/drink, feed, quasi-drugs, pharmaceuticals, etc. because of being high in safety and practicability as well as promising the effects of preventing aging-associated senility and diseases.  &lt;P&gt;SOLUTION: The composition is such as to function to regulate the quantity change of a cell death (especially apoptosis) marker protein as aging proceeds so as to diminsh the change. This composition contains an amla (Embilica officinale) extract as active ingredient. By the way, the cell death marker protein means, e.g. a protein that is present in cells and functions on mitochondria envelope, for example, being Bax or Bcl-2 protein.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:An improver for hypoxia, containing a specific benzoazepine derivative or a salt thereof as an active ingredient, having improving action on hypoxia and useful as a cerebral activator, drug for consciousness disorder caused by cerebrovascular disorder, etc., drug for senile dementia, etc. CONSTITUTION:An improver for hypoxia containing a benzoazepine derivative expressed by formula I (R&lt;1&gt; is H, lower alkyl, etc.; R&lt;2&gt; is phenyl which may have 1-3 substituent groups, e.g. halogen, lower alkyl, etc.; A is lower alkylene). specifically the improver can be effectively used as a cerebral activator, improving drug for consciousness disorder caused by cerebrovascular disorder, encephalitis, metabolic disorder, etc., drug for senile dementia and preventing agent for arrhythmia or cardiac failure caused by oxygen shortage, etc. The compound expressed by the formula is capable of removing active oxygen species, has also preventing action on formation of peroxide lipid in the living body and is useful as an antiarteriosclerotic agent, anti-inflammatory agent, remedy for cataract, etc.
The present invention relates to a purified, easily produced poly- beta -1-&gt;4-N-acetylglucosamine (p-GlcNAc) polysaccharide species. The p-GlcNAc of the invention is a polymer of high molecular weight whose constituent monosaccharide sugars are attached in a  beta -1-&gt;4 conformation, and which is free of proteins, and substantially free of single amino acids, and other organic and inorganic contaminants. In addition, derivatives and reformulations of p-GlcNAc are described. The present invention further relates to methods for the purification of the p-GlcNAc of the invention from microalgae, preferably diatom, starting sources. Still further, the invention relates to methods for the derivatization and reformulation of the p-GlcNAc. Additionally, the present invention relates to the uses of pure p-GlcNAc, its derivatives, and/or its reformulations.
PROBLEM TO BE SOLVED: To obtain a neoplastic vessel occlusion agent effectively usable for the photochemical therapy of neoplastic vessel in various tissues in the eye or other living tissues and having high safety. SOLUTION: This agent contains &gt;=0.1wt.%, preferably 2-60wt.% of a tetrapyrrole derivative of formula ((n) is 1 or 2) or its salt as an active component. The unit preparation for oral administration preferably contains 50-300mg of the active component compound. It is administered at a daily dose of 0.2-10mg for adult once a day. The agent is especially effective for the treatment of aging macular degeneration caused by the generation of choroidal neovascularity in ophthalmologic region or proliferative lesion in diabetic retinopathy caused by retina neovascularization. The compound of formula is highly accumulated in the vessel in the eye after administration and the neoplastic vessel in the choroid or retina by irradiating the restricted vessel area with a laser beam.
FIELD: medicine, gynecology. SUBSTANCE: pseudoerosion of uterine cervix should be treated with the flow of plasmochemical sodium oxide for 30-60 sec followed by carrying out application with &#34;Sanguicol&#34; collagen sponge. Procedures are conducted twice weekly, total quantity of procedures corresponds to 8-10. The method enables to exclude hemorrhages and conduct therapy at any phase of menstrual cycle. EFFECT: higher efficiency of therapy. 1 ex
PURPOSE: To obtain a pharmaceutical preparation capable of selectively and surely releasing a pharmacodynamically effective ingredient in the colon with good reproducibility by coating a composition containing the pharmacodynamically effective ingredient with a base containing a polymeric substance, having a specific intrinsic viscosity and decomposable in the colon. CONSTITUTION: This pharmaceutical preparation is obtained by coating a composition containing a pharmacodynamically effective ingredient with a base, having 0.2-2dl/g intrinsic viscosity and decomposable in the colon to preferably 10-200μm thickness. For example, a copolymer comprising structural units of formulas I and II [R is a bivalent organic group; R&lt;1&gt; is a saccharide residue decomposed or assimilated in the colon; X&lt;1&gt; and X&lt;2&gt; are each O, S, etc.; R&lt;2&gt; is a polyalkylene, a polyamide, etc.] is cited as the polymeric substance decomposable in the colon. A copolymer in which a dibasic acid constituting the units I and II is terephthalic or isophthalic acid, a saccharide constituting the unit I is cellobiose and a polyalkylene glycol constituting the unit II is polytetramethylene glycol or polypropylene glycol is preferred as the copolymer.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide peptides exhibiting immunochemical reaction to antibodies against Epstein-Barr virus (EBV) which is human herpes virus, and monoclonal antibodies and anti-idiotypic antibodies against these peptides.  &lt;P&gt;SOLUTION: The invention relates to a peptide or fragment thereof which is immunochemically reactive with Epstein-Barr Virus (EBV) antibodies. A new monoclonal antibody directed to the peptide or fragment thereof is also part of the invention. The invention also relates to a method for the detection of EBV or anti-EBV antibodies in a test fluid and also to an immunochemical reagent comprising a peptide, a fragment or a polypeptide according to the invention and a test kit to be used when applying the detection methods. Detection of EBV in a test fluid or tissue specimen using antibodies, monoclonal and polyclonal, directed to the peptide, which have the characteristics of detecting both native and denatured intact, functional EBNA-1 protein is also part of the present invention.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The present invention relates to a computer-implemented methods and apparatus for remote cognitive and/or perceptual testing using a computer network having a remote computer geographically separate from an administering computer. The remote cognitive and/or perceptual testing includes administering a set of cognitive and/or perceptual tests, obtaining a performance response of the person to the tests and uploading the testing information via the computer network. The tests may be administered a number of times to evaluate one or more cognitive skills and/or perceptual abilities. Parallel to the testing, a therapy may be administered. The method may also include monitoring the performance of the person on the tests. The computer-implemented method may additionally include administering a set of initial tests before therapy inception to assess a person&#39;s intrinsic cognitive skills and/or perceptual abilities. The results of the initial testing and testing during therapy may be entered into a database. The database may be built from the performance response of multiple people and may be useful in predicting efficacy of a proposed therapy.
NEW MATERIAL:The phenoxyacetic acid derivative of formula I [A is (substituted)5-pyrazolyl; R&lt;1&gt; is H or lower alkyl; R&lt;2&gt; is H or lower alkenyl; X is halogen; Z is O or methylene] or its salt. EXAMPLE:[2,3-Dichloro-4-( 1-ethoxymethyl-5-pyrazolylcarbonyl )phenoxy]acetic acid ethyl ester. USE:A drug having diuretic action, electrolyte excretion promoting action and uric acid excretion promoting action. Remedy and preventive for congestive heart failure, various edemata, pulmonary edema, ascites, pleurotic exudation, interstitial nephritis, gout, hyperuricemia, etc. PREPARATION:The compound of formula I can be produced e.g. by reacting a phenol derivative of formula II with an acetic acid derivative of formula III.
A compound of formula (I), wherein; R is alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group, optionally substituted by one or more hydroxyl groups; cycloalkyl; optionally substituted cycloalkanyl; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be saturated, or fully or partially unsaturated and which may optionally be substituted by one or more alkyl groups or halo atoms; or R is optionally substituted phenyl or a compound of formula (a), wherein; X is O, S or -CH2 -; a, b, e, and d are each independently selected from an integer 0 to 2 and a+b+c+d &lt; 5; or R is R24 , wherein  R24 is H, optionally substituted alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl; or optionally substituted cycloalkyl or cycloalkenyl; or an optionally substituted 3 to 6 membered oxygen or sulphur containing a heterocyclic ring; or a group of formula SR23, wherein R23 is alkyl, alkenyl, alkylnyl, cycloalkyl, cycloalkenyl, or optionally substituted phenyl. R4 is H or an acyl of an organic acid of up to 18 carbons. The compounds of this invention are useful as antibacterial agents and antiprotozoa agents and for other applications (e.g. anticancer, atherosclerosis, gastric motility reduction, etc.) in mammals, including man, as well as in fish and birds. The invention also relates to pharmaceutical compositions containing such compounds and to methods of treating bacterial protozoa infections by administering such compounds. The invention also relates to methods of preparing such compounds and to intermediates useful in such preparation.
PROBLEM TO BE SOLVED: To provide a method for reduction of antibiotic usage in the livestock industry.SOLUTION: A pharmaceutical composition for use in reducing the need to administer antibiotics to a non-human animal contains 4&#39;-fluoro-4-(4-(2 pyridyl)-1-1-piperazinyl-butyrophenone (azaperone) represented by the formula (1) as an active ingredient. The pharmaceutical composition is continuously orally administered to the animal in a dose ranging from 0.5 to 3.0 mg/kg/day on an azaperone basis. The composition is administered together with food or drinking water. The pharmaceutical composition is continuously orally administered to the animal in a concentration ranging from 2 to 13.0 mg on an azaperone basis per liter drinking water. The composition is administered for one to six days. The non-human animal is selected from poultry, ruminants and pigs.
Management of patient activities for a clinician is described herein. A patient activity list provides a common view of activities for patients assigned to a clinician for a given time period, such as a shift. The patient activity list provides a simplified view with critical indicators providing critical patient information. Patient activities may include ad hoc activities and scheduled activities presented in a timeline view based on the scheduled time period for each respective activity. Only activities relevant to the clinicians role are included and each activity is represented as a graphical icon representative of the type of activity. The patient activity list is fully navigable to allow the clinician to access further information and complete activities within context of the clinician&#39;s activities.
PURPOSE:To obtain a powdery royal jelly having good keeping quality and handleability without causing muddiness and precipitate by subjecting an aqueous alkali solution of royal jelly to coagulate protein and separating and removing the coagulated protein by controlling pH, temperature and concentration of alcohol added. CONSTITUTION:An alkali such as sodium carbonate, normally 15-20% aqueous solution thereof is added to 100 pts.wt. royal jelly at an amount of 0.05-0.15 pts.wt. and the mixture is homogenized using a homogenizer. 95-105 pts.wt. water is added thereto to dilute the mixture and the mixture is controlled to &lt;=pH3 by hydrochloric acid, etc. The ethanol is added to the mixture so as to become 70-80w/w% ethanol concentration and the mixture is heated at 45-55 deg.C for about 15-30min and the main ingredient is extracted into the solution while coagulating protein. Then the mixture containing the coagulated protein is cooled to &lt;=30 deg.C and controlled to pH5.0-5.4, the ethanol concentration is controlled to &gt;=50w/w% and the coagulated protein is eliminated. Then a vehicle such as water soluble dextrin (having &gt;=50wt.% solid content) is added thereto and subjected to freeze-drying to provide the powdery royal jelly for drink.
PROBLEM TO BE SOLVED: To obtain the subject action-improving agent effective for promoting the action of an oral cavity enzyme to exhibit its effect by including a component selected from a nonionic surfactant, an amino acid-based anionic surfactant, a polyethylene glycol, a polymeric polysaccharide and a sugar alcohol. SOLUTION: The objective action-improving agent to be used in combination with an oral cavity enzyme such as dextranase to improve the action of the enzyme can be produced by including a component selected from (A) a nonionic surfactant (e.g. decaglyceryl monomyristate), (B) an amino acid-based anionic surfactant (e.g. lauroylmethyl-β-alanine sodium), (C) a polyethylene glycol having an average molecular weight of preferably &lt;=1,000, (D) a polymeric polysaccharide (e.g. pectin) and (E) a sugar alcohol (e.g. glycerol). The action-improving agent is used preferably in an amount of &gt;=0.001 pt.wt. based on 1 pt.wt. of the above oral cavity enzyme.
NEW MATERIAL:A compound of formula I (R is H, benzoyl). EXAMPLE:1-(3-Deoxy-3-fluoro-beta-D-ribofuranosyl)-5-fluorouracil. USE:Antitumor agent. PREPARATION:A furanoside derivative of formula II (R&lt;1&gt; is alkoxy, halogen; R&lt;2&gt;, R&lt;3&gt; are protecting groups; Y is H, eliminating group) is fluorinated to introduce the fluorine atom in the 3-position. When needed, the product is deprotected. Then, residue of 5-fluorouracil group is introduced to give the compound of formula I. The fluorinating agent is suitably a fluorinated tetraalkyl or aralkylammonium and is used in the inert solvent in the form of a solution. The fluorination is conducted at 0 deg.C to room temperature. The compound of formula II has to be synthesized stereospecifically. Further, the hydroxyl groups other than the 3-position should be protected so that they are not fluorinated.
&lt;P&gt;PROBLEM TO BE SOLVED: To develop an external preparation for the skin free from irritation and unpleasant odor, excellent in storage property and antimicrobial properties and increasing a moisture-retaining property and a heat-insulating property.   &lt;P&gt;SOLUTION: The external preparation for skin is obtained by dissolving seaweed in an aqueous solution of a monovalent alkali to provide paste and neutralizing the paste. The monovalent alkali is preferably sodium carbonate. Oil, mineral water, an essential oil and/or a clay mineral may be added thereto. The sodium concentration is preferably 1.4-2.1 and the oil is preferably contained in an amount of 2-10% based on total amount. The external preparation for skin may be used as a pack cosmetic.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
Aqueous solutions of glucosides and alkaloids which are normally insoluble or only sparingly soluble in water are made by the addition of water-soluble amides of aromatic or heterocyclic carboxylic acids, if desired in admixture with water - soluble aliphatic acid amides. An example is given of the use of b -pyridine-carboxylic acid diethylamide for increasing the solubility of caffeine in water. Other solubilizing agents mentioned are N-methylbenzamide, N : N&lt;1&gt; - dimethylbenzamide, p - toluylic acid dimethylamide, a - and #c-pyridine-carboxylic acid diethylamides, 4 - methylpyridine - 3 - carboxylic acid diethylamide, and mixtures thereof with acetamide, propionic acid diethylamide and isovalerianic acid dimethylamide.  As materials to be solubilized are further mentioned quinine, atropine, strychnine, g-strophanthine, digitalis lanata glucoside, theobromine, and theophylline.ALSO:Aqueous solutions of glucosides and alkaloids which are normally insoluble or only sparingly soluble in water are made by the addition of water-soluble amides of aromatic or heterocyclic carboxylic acids, if desired in admixture with water-soluble aliphatic acid amides.  An example is given of the use of b -pyridinecarboxylic acid diethylamide for increasing the solubility of caffeine in water.  Other solubilizing agents mentioned are N-methylbenzamide, N : N1-dimethylbenzamide, a - and \su-pyridinecarboxylic acid diethylamides, 4-methylpyridine-3-carboxylic acid diethylamide and mixtures thereof with acetamide, propionic acid diethylamide and isovalerianic acid dimethylamide.  As materials to be stabilized are further mentioned quinine, atropine, strychnine, g-strophanthine, digitalis lanata glucoside, theobromine, and theophylline.
PROBLEM TO BE SOLVED: To provide the spatial transmission network system of medicine preparation medical treatment care information capable of flexibly and easily coping with the extension and change of equipment and efficiently supporting a medicine preparation medical treatment job without errors not depending on the processor of high performance. SOLUTION: An information carrier 21 is attached to a medicine tray moved on a medicine preparation line and data communication by spatial transmission is performed with the fixed port 31 of a prescription instruction unit 30 connected to a communication path 3. The information carrier 21 is provided with a CPU 215 and E&lt;2&gt; PROM 216. In the E&lt;2&gt; PROM 216, other than a processing program, the medicine preparation information of prescription data or the like and medicine preparation medical treatment management information such as process order information, scheduled required time information and processing condition information, etc., are stored. The spatial transmission between the information carrier 21 and the fixed port 31 and the read/write of data to the E&lt;2&gt; PROM 216 are autonomously performed.  The information carrier 21 performs the data communication with other processing units through the communication path 3.
PURPOSE:To provide the titled remedy composed of a mixture obtained by grinding rice bran together with nearly the same weight of garlic, or composed of the concentrated extract of the mixture. CONSTITUTION:A 1:1 (weight ratio) mixture of rice bran and garlic is ground to obtain a remedy for the diseases such as foot trychophytosis, (athlete&#39;s foot), tinea trichophytia (ringworm), etc. caused by a trychophyton which is a kind of mold. It can be applied to various symptoms of foot trychophytosis (e.g. vessicle, sore, corneous, nail, etc.). The above components are absolutely ineffective when used separately; however, high additive effect can be attained by the combination of the components to exhibit a remarkably high drug action. The mixture obtained by grinding both components can be used as it is (in the form of ointment) or as an extract (liquid) with water, and the same drug action can be obtained in both cases.
FIELD: chemical-pharmaceutical industry. SUBSTANCE: invention relates to a medicinal form as suppository containing erythromycin. Drug has erythromycin and a base - solid confectionery fat on the basis of plasticized hydrogenated fat or &#34;Vitepsol&#34; at the following content of components, g/suppository (mass is 1.15-1.40 g): erythromycin 0.4-0.12, and a base - the rest. Invention provides high therapeutic effectiveness, maximal concentration of blood erythromycin is occurred in 120-135 min. An agent shows high antibacterial effect. The proposed drug shows high stability at storage and retains physical-chemical properties for 2-2.5 years without alternations. EFFECT: enhanced effectiveness of an agent. 2 tbl